- $218.74bn
- $245.09bn
- $54.07bn
- 98
- 39
- 90
- 89
REG - AstraZeneca PLC - Baxdrostat met primary endpt in BaxHTN PhIII trial
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in the EU for bladder cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Datroway approved in US for EGFRm lung cancer
AnnouncementREG - Niox Group PLC AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - AstraZeneca enters into collaboration with CSPC
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Fixed-duration Calquence approved in EU for 1L CLL
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi recommended in EU for bladder cancer
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - Acquisition of EsoBiotec completed
AnnouncementREG - AstraZeneca PLC - Imfinzi improved DFS in early bladder cancer
AnnouncementREG - AstraZeneca PLC - Enhertu improved pCR in early-stage breast cancer
AnnouncementRCS - Redx Pharma Limited - Redx presents Ph1 data supporting RXC008 at DDW
AnnouncementREG - AstraZeneca PLC - Calquence combination approved in EU for 1L MCL
AnnouncementREG - AstraZeneca PLC - Breztri met primary endpoints in Ph3 asthma trials
Announcement